Related Experiment Video
Updated: Jul 7, 2026

Vessel-sparing Excision and Primary Anastomosis
Published on: January 7, 2019
Delayed presentation in posterior urethral valve: long-term implications and outcome
M S Ansari1, Pratipal Singh, Anil Mandhani
1Department of Urology and Renal Transplantation, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India. ansarimsa@hotmail.com
Insights
Delayed presentation of posterior urethral valves (PUV) in children over 2 years old is associated with higher risks of azotaemia and chronic renal insufficiency. Early diagnosis and intervention are crucial for better long-term outcomes in PUV patients.
Area of Science:
- Pediatric Urology
- Nephrology
- Surgical Outcomes
Background:
- Posterior urethral valves (PUV) are a common congenital anomaly in male infants.
- Delayed diagnosis of PUV can lead to significant renal damage and long-term complications.
Purpose of the Study:
- To analyze the impact of delayed presentation of posterior urethral valves on long-term outcomes in children.
- To identify prognostic factors for children with PUV.
Main Methods:
- A retrospective analysis of 194 children with PUV who underwent surgical ablation.
- Patients were divided into two groups based on age at presentation: Group I (<2 years) and Group II (>2 years).
- Data on presenting complaints, azotemia, serum creatinine, surgical outcomes, and long-term renal function were analyzed.
Main Results:
- Group II (late presenters) showed significantly higher rates of azotemia (81.8% vs 32.6%) and higher mean serum creatinine levels compared to Group I.
- Voiding improvement after ablation was significantly lower in Group II (20.4% vs 86.1%).
- Long-term renal insufficiency developed in 40.8% of Group II patients versus 30.5% of Group I patients.
Conclusions:
- Delayed presentation of PUV beyond 2 years of age is associated with poorer outcomes, including a higher risk of chronic renal insufficiency.
- Serum creatinine levels at presentation and 1 year post-ablation, along with persistent VUR and voiding dysfunction, are key prognostic indicators.
- Pediatric patients with PUV presenting after 2 years require cautious management due to increased risks.
Objectives:
To analyze the effect of delayed presentation of posterior urethral valves in children.
Methods:
We divided 194 children with posterior urethral valve (PUV) who underwent surgical ablation into group I (less than 2 years old) and group II (greater than 2 years old) according to age at presentation. We analyzed the data for the effect of various parameters on post-valve fulguration long-term outcomes.
Results:
Groups I and II had 95 and 99 children, respectively. Poor urinary stream or crying during micturition was the most common presenting complaint (96%) in both groups. A total of 32.6% and 81.8% patients had azotaemia at the time of diagnosis in groups I and II, respectively (P <0.001). Mean serum creatinine was 1.68 mg% and 4.1 mg% in groups I and II, respectively (P <0.05). Primary valve ablation was performed in 85.5% patients. After valve ablation, voiding improved in 86.1% and 20.4% patients in groups I and II, respectively (P = 0.001). At a mean follow-up of 9.8 years, 30.5% and 40.8% patients developed renal insufficiency in groups I and II, respectively (P <0.05). Serum creatinine level at 1 year after valve ablation and at presentation was the main prognostic factor for groups I and II, respectively, whereas persistence of VUR and voiding dysfunction after valve ablation reflected poor prognosis for both groups.
Conclusions:
Patients with PUV presenting after 2 years should be treated with caution because the condition is potentially hazardous and these patients are at a higher risk of developing chronic renal insufficiency on long-term follow-up.
Related Concept Videos
Mitral Valve Prolapse I: Introduction
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Mitral Valve Prolapse II: Assessment and Management
Mitral Valve Prolapse III: Nursing Management
Urinary Tract Calculi VI: Surgical Management
Urinary Tract Infection II: Pathophysiology
